表皮生长因子受体和蛋白激酶B在胃癌组织中的表达及临床意义

Expression and clinical significance of epidermal growth factor receptor and protein kinase B in gastric carcinoma

目的探讨胃癌组织表皮生长因子受体（EGFR）和蛋白激酶B（AKT）在胃癌组织中的表达与胃癌临床病理特征及预后的关系。方法采用免疫组织化学方法检测84例胃癌组织和15例非癌胃组织中EGFR和AKT的表达情况，并分析其表达与胃癌患者临床病理特征及预后的关系。结果EGFR和AKT在胃癌组织的阳性表达率分别为55．9％（47／84）和64．3％（54／84）,明显高于非癌胃组织的20．0％（3／15）和6．7％（1／15），差异均有统计学意义（P〈0．05，P〈0．01）。EGFR表达与胃癌分期有关，AKT表达则与胃癌淋巴结转移有关（均P〈0．01）。EGFR阴性表达和阳性表达患者5年总体生存率分别为49％和22％（P〈0．05）；AKT阴性表达和阳性表达患者5年总体生存率分别为45．7和30．2％（P〈0．05）。结论检测胃癌组织中的EGFR和AKT的表达，有助于判断胃癌恶性程度及评估预后。

Objective To evaluate the association between survival and expressions of epidermal growth factor receptor （EGFR） and protein kinase B （AKT） in gastric carcinoma specimens. Methods EGFR and AKT were detected by immunohistochemistry in 84 patients with gastric cancer and 15 controls. Association between their expressions and clinical characteristics as well as prognosis were analyzed. Results In patients with gastric cancer, expression rates were significantly higher than those in 15 normal gastric tissues for EGFR（55.9% vs. 20%,P〈0.05） and AKT（64.3% vs. 6.7%, P〈O.01）. Expression of EGFR was associated with late staging （P〈O.01）, while expression of AKT was assoicated with lymph node metastasis （P〈0.01）. Overall 5-year survival rate was significantly higher in patients with EGFR negative expression （49.0% vs. 22.0%, P〈0.05）. Overall 5-year survival rate was significantly higher in patients with AKT expression（45.7% vs. 30.2%,P〈0.05）. Conclusion Expression of EGFR and AKT negative may be used to evaluate the degree of differentiation and prognosis in patients with gastric carcinoma.